tradmap

KARD Kardigan, Inc.

$20.86 +0.70%

Updated

Healthcare · Pharmaceutical Preparations

Kardigan, Inc. (KARD) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $2.0 billion. Shares last traded at $20.86, 30.3% below their 52-week high.

Market Cap
$2.0B
Shares Out
93.5M
EPS (TTM)
P/E Ratio
P/S Ratio
P/B Ratio
3.17
Dividend / Share
Dividend Yield
52-Week High
$29.90
52-Week Low
$16.33
Volume
13,047
Avg Vol (3m)
25,970.345

Performance

1W
+3.78%
1M
+2.73%
3M
6M
YTD
-5.20%
1Y

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
49.71
SMA (50)
$21.65
SMA (200)
Price vs SMA50
-3.67%
Price vs SMA200
ATR (14)
$1.41

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
Net Income
Gross Margin
Operating Margin
Net Margin
Return on Equity
Return on Assets
Current Ratio
8.72
Debt / Equity
0.17
Revenue Growth (YoY)

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-8.66 2026-08-11
Q2 2026 $-6.27 2026-08-11

Full earnings history →

Pharmaceutical Preparations peers

KARD vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated

1–14 of 14
LLYLilly (Eli)$1.09T40.8613.7033.5%-0.02%
JNJJohnson & Johnson$670.6B31.886.8521.5%+1.04%
ONCBeone Medicines Ltd.$535.9B817.2587.4310.7%+0.23%
ABBVAbbVie$459.8B72.877.149.8%-0.57%
MRKMerck$375.8B118.445.654.8%+0.44%
ABTAbbott Laboratories$189.5B30.204.2013.9%-1.50%
PFEPfizer$164.2B37.912.586.8%-0.76%
VRTXVertex Pharmaceuticals$141.5B32.1111.2435.0%+0.24%
BMYBristol Myers Squibb$139.1B14.982.8318.9%+0.62%
REGNRegeneron Pharmaceuticals$87.2B20.155.6127.9%-1.02%
TEVATeva Pharmaceutical Industries Ltd$42.6B60.412.464.1%-2.32%
ALNYAlnylam Pharmaceuticals$35.4B43.779.5221.8%-1.10%
ZTSZoetis$31.5B12.053.3127.5%+0.16%
RPRXRoyalty Pharma Plc$28.2B34.5611.1132.1%+1.24%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.